RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA
Clinical trials for RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…
Matched conditions: RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Matched conditions: RECURRENT PERITONEAL MALIGNANT MESOTHELIOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC